HARNESSING THE FULL POTENTIAL OF FRONTLINE IMMUNOTHERAPY IN ADVANCED NSCLC

Join us in Vienna for the first ever Clinical Olympics™ to be held during IASLC! Attendees will join 1 of 3 teams to compete in a series of Clinical Events, answering challenge questions - via iPad - on immunotherapy in non-small cell lung cancer (NSCLC). Individual learners will earn points for their chosen country with correct responses in each event. After each team competition is completed, and at the conclusion of the overall symposium, a Team Leader Board will appear on the big screens to show comparative scores across teams as the Gold, Silver, and Bronze medals are awarded for each event and for all-around performance in the Clinical Olympics™.

The treatment landscape for advanced NSCLC continues to rapidly evolve with the advent of newly targetable driver mutations and an ever-expanding plethora of immunotherapeutic regimens. In this symposium, participants will join an esteemed panel to receive expert insights — in an interactive, gamified manner — on evidence-based strategies for biomarker testing, optimal selection of checkpoint inhibitor regimens, and toxicity management.

FACULTY

Jared M. Weiss, MD
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, United States

Prof. MUDr. Aleš Ryška, MD, PhD
Charles University
Hradec Králové University Hospital
Prague, Czech Republic

Mihaela Aldea, MD, PhD
Paris-Saclay University
Gustave Roussy
Villejuif, France

PROGRAM AGENDA

17:45 - 18:00  Registration
18:00 - 18:05  Opening Ceremonies
18:05 - 18:20  EVENT #1:
Use of Biomarker Testing in Advanced NSCLC
Prof. MUDr. Aleš Ryška, MD, PhD
18:20 - 18:35  EVENT #2:
Selecting Frontline Immunotherapy in Advanced NSCLC
Jared M. Weiss, MD
18:35 - 18:50  EVENT #3:
Managing Immunotherapy-Related Adverse Events in NSCLC
Mihaela Aldea, MD, PhD
18:50 - 19:00  Closing Ceremonies and Presentation of Medals
Jared M. Weiss, MD

This educational activity was independently developed by RMEI Medical Education, LLC. All faculty and planner relevant financial relationships were identified and mitigated and RMEI Medical Education, LLC has reviewed the content and determined it to be fair, balanced, and without commercial bias.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

This program was approved by the IASLC 2022 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.